Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 160-170

  Pettersson, Helen M ^a   Pietras, Alexander ^a   Persson, Matilda Munksgaard ^a   Karlsson, Jenny ^a   Johansson, Leif ^a   Shoshan, Maria C ^b   Påhlman, Sven ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BIOLOGICAL MARKER; CALPAIN; CARBOPLATIN; CASPASE 3; CHROMOGRANIN A; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MARKER; PROTEIN BCL 2; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL DEATH; CELL DIFFERENTIATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE INCREASE; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; BCL-2-ASSOCIATED X PROTEIN; BIOLOGICAL MARKERS; CASPASE 3; CELL DEATH; CELL DIFFERENTIATION; CELL HYPOXIA; CELL LINE, TUMOR; ENZYME ACTIVATION; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; OXIDES; SMALL CELL LUNG CARCINOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149498185     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0595     Document Type: Article

References (40)

1. Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev 2004;30:521-43.
2. Chen LC, Travis WD, Krug LM. Pulmonary neuroendocrine tumors: what (little) do we know? J Natl Compr Canc Netw 2006;4:623-30.
3. Freyer G, Tranchand B, Ligneau B, et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol 2000;50:315-24.
4. Inoue A, Saijo Y, Kikuchi T, et al. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol 2004;15:51-4.
5. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
6. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-8.
7. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-24.
8. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60.
9. Øra I, Bondesson L, Jonsson C, et al. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000;277:179-85.
10. Karlsson J, Øra I, Pörn-Ares I, Påhlman S. Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin Cancer Res 2004;10:3179-88.
11. Karlsson J, Edsjo A, Påhlman S, Pettersson HM. Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia. Mol Cancer Ther 2005;4:1128-35.
12. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
13. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-53.
14. Cai X, Shen YL, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000;14:262-70.
15. McCafferty-Grad J, Bahlis NJ, Krett N, et al. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther 2003;2:1155-64.
16. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H. PML induces a novel caspase-independent death process. Nat Genet 1998;20:259-65.
17. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1h-converting enzyme-like proteases. Proc Natl Acad Sci U S A 1996;93:14559-63.
18. Karlsson J, Pietras A, Beckman S, Pettersson HM, Larsson C, Påhlman S. Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax. Oncogene 2007;26:6150-9.
19. Johnson BE, Russell E, Simmons AM, et al. MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J Cell Biochem Suppl 1996;24:210-7.
20. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
21. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, et al. Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell 2006;10:413-23.
22. Lofstedt T, Jogi A, Sigvardsson M, et al. Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem 2004;279:39223-31.
23. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
24. Gobeil S, Boucher CC, Nadeau D, Poirier GG. Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Differ 2001;8:588-94.
25. Hood JL, Brooks WH, Roszman TL. Subcellular mobility of the calpain/calpastatin network: an organelle transient. Bioessays 2006;28:850-9.
26. Wood DE, Newcomb EW. Cleavage of Bax enhances its cell death function. Exp Cell Res 2000;256:375-82.
27. Mandic A, Viktorsson K, Strandberg L, et al. Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. Mol Cell Biol 2002;22:3003-13.
28. Blomgren K, Zhu C, Wang X, et al. Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia: a mechanism of "pathological apoptosis"? J Biol Chem 2001;276:10191-8.
29. Waterhouse NJ, Finucane DM, Green DR, et al. Calpain activation is upstream of caspases in radiation-induced apoptosis. Cell Death Differ 1998;5:1051-61.
30. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043-52.
31. Scholz C, Wieder T, Starck L, et al. Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 2005;24:1904-13.
32. Carney DN, Mitchell JB, Kinsella TJ. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res 1983;43:2806-11.
33. Gazdar AF, Carney DN, Nau MM, Minna JD. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res 1985;45:2924-30.
34. Radice PA, Matthews MJ, Ihde DC, et al. The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell subtypes. Cancer 1982;50:2894-902.
35. Bergh J, Larsson E, Zech L, Nilsson K. Establishment and characterization of two neoplastic cell lines (U-1285 and U-1568) derived from small cell carcinoma of the lung. Acta Pathol Microbiol Immunol Scand [A] 1982;90:149-58.
36. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 2002;70:292-9.
37. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004;101:5328-35.
38. Rojewski MT, Korper S, Schrezenmeier H. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma 2004;45:2387-401.
39. Amadori S, Fenaux P, Ludwig H, O'Dwyer M, Sanz M. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin 2005;21:403-11.
40. Pettersson HM, Karlsson J, Pietras A, Øra I, Påhlman S. Arsenic trioxide and neuroblastoma cytotoxicity. J Bioenerg Biomembr 2007;39:35-41.